Symbols

HALO

Halozyme Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 2

Consensus Rating "Strong Buy"

MACD Golden Cross

Ample Liquidity

High Gross Profit Margin

Gap Up

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About HALO

Halozyme Therapeutics, Inc.

A biopharmaceutical company that develops recombinant human enzymes and novel oncology therapies for the tumor microenvironment

Industry

Biological Technology

Established Date

Listing Date

05/10/2007

Exchange

NASDAQ Stock Exchange

Full-time Employees

423

Fiscal Year Ends

12-31

Website

www.halozyme.com

Security Type

Common stock

Office address

12390 El Camino Real, San Diego, California, 92130

Business

Introduction

Halozyme Therapeutics, Inc., founded in 1998 and re-incorporated from Nevada in Delaware in November 2007, is a biopharmaceutical company focused on developing and commercializing innovative therapies that improve patient care. The company's research centers on the extracellular matrix, and the structural network surrounding the cell plays a crucial role in tissue integrity, cell signaling, migration and survival. With extensive expertise accumulated through years of research, Halozyme leverages its deep scientific understanding of ECM to develop new therapeutic methods and drug delivery technologies for this complex and biologically rich environment, aiming to advance the next generation of therapeutic solutions.

Company Financials

EPS

HALO has released its 2025 Q4 earnings. EPS was reported at -0.24, versus the expected 1.9, missing expectations. The chart below visualizes how HALO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

HALO has released its 2025 Q4 earnings report, with revenue of 451.77M, reflecting a YoY change of 51.60%, and net profit of -141.59M, showing a YoY change of -203.34%. The Sankey diagram below clearly presents HALO's revenue sources and cost distribution.